Sobi Reports Significant Revenue Growth Surpassing Estimates
Swedish Orphan Biovitrum AB (publ) (Sobi) has announced a noteworthy increase in its revenue for the full year 2024, with figures surpassing earlier estimations. The projected full-year revenue reached approximately SEK 26,000 million, reflecting an impressive growth rate of about 19% when assessed at constant exchange rates.
Key Drivers Behind Revenue Increase
A considerable part of this growth can be attributed to higher-than-expected sales in the fourth quarter, especially within the Haemophilia portfolio and Kineret. Each segment has shown remarkable performance, contributing to the overall success.
Altuvoct's Market Penetration
The new product, Altuvoct, has experienced a higher-than-anticipated rate of patient transitions, particularly in key markets recently opened, such as Germany and Switzerland. This enthusiastic adoption plays a crucial role in bolstering Sobi's revenue.
Elocta's Resilience in Market
Alongside Altuvoct, Elocta has benefited from a growing patient base. Notably, in regions where Altuvoct has been launched, there has been a lesser frequency of patients switching from Elocta than forecasted. This trend has also led to favorable gross-to-net effects on sales figures.
Alprolix and Kineret Contributions
The Alprolix product line has seen a significant influx of new patients and a rise in on-demand treatments across Europe, enhancing its sales figures even further. Similarly, Kineret has outperformed expectations due to beneficial gross-to-net adjustments and increased market demand.
Financial Performance Analysis
Sobi's adjusted EBITA margin was observed to be in the mid-30s percent range of revenues. While the stronger revenue performance is commendable, it was slightly offset by a combination of negative mix effects on the gross margin and investments in launch and pipeline products during the fourth quarter.
Outlook for the Future
In the earnings released with the Q3 report, Sobi previously set the expectation for 2024 revenue growth at a mid-teens percentage at constant exchange rates, with the adjusted EBITA margin anticipated to remain around the mid-30s percent of total revenue. This indicates a consistent growth trajectory and a commitment to maintaining robust margins.
Upcoming Financial Update
On February 5, 2025, Sobi will provide further insights by releasing its fourth-quarter and full-year 2024 financial report. This upcoming announcement is highly anticipated as stakeholders aim to assess the performance post the extensive growth reported.
About Sobi
Sobi is a specialized biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases. The company ensures reliable access to groundbreaking treatments across multiple fields, including haematology and immunology. Sobi operates globally, employing approximately 1,800 individuals across various continents. The company made significant strides, achieving a revenue milestone of SEK 22.1 billion in 2023. Additionally, Sobi's stock is publicly traded under the ticker STO:SOBI on Nasdaq Stockholm, illustrating its strong market presence.
Frequently Asked Questions
What is the reported revenue for Sobi in 2024?
Sobi reported a full-year revenue of approximately SEK 26,000 million for 2024, showing a 19% growth at constant exchange rates.
What contributed to the revenue increase for Sobi?
The revenue increase was primarily due to significant sales growth in the Haemophilia portfolio and the Kineret product line.
How has Altuvoct performed in the market?
Altuvoct has shown higher-than-expected patient transitions, particularly in markets such as Germany and Switzerland, driving sales higher.
What are the anticipated EBITA margin figures for Sobi?
Sobi expects the adjusted EBITA margin to remain in the mid-30s percent range of revenues, maintaining strong financial health.
When will Sobi release its next financial report?
Sobi plans to announce its fourth-quarter and full-year 2024 report on February 5, 2025, providing insights into its ongoing performance.
